Summarized by Masters of Longevity from Longevity Technology.
Inmune Bio and a quantum computing firm team up on an article about using quantum optimization and AI to guide drug-research priorities, starting with Alzheimer's and rare-disease directions.
Key Takeaways
- Inmune Bio will combine its clinical datasets with quantum optimization and AI to identify diseases and biomarkers linked to XPro targets.
- The collaboration will begin by prioritizing indications, focusing on rare diseases to enable smaller, faster, and more capital-efficient trials.
- The initial engagement is QCi’s first commercial pharmaceutical/biotech partnership and includes options for further work as clinical programs advance.
